Re: Marketing and use of TB Platinum for active TB in India and high TB burden countries

Leading doctors, advocacy groups, medical organizations and U.S. TB programs call upon Sanofi to lower the price of rifapentine to ensure its accessibility and continue and expand its investments in the development of the drug for active TB.

Survey shows HIV pipeline healthy, HCV drug development surging, while TB research moves forward much too slowly; Faster research, approval, and access demanded.

Threshold for starting treatment raised to CD4 count of 500. The Organization continues to recommend that all people with HIV with active TB receive antiretroviral therapy irrespective of CD4 cell count.

Roadmap of TB/HIV sessions at the upcoming 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention.

Sequestration-related cuts are threatening to damage the CDC’s Tuberculosis Trials Consortium, the leading TB clinical research collaborative in the world.

Tuberculosis patients and activists protested outside the federal health ministry in New Delhi Wednesday, angered at a shortage of life-saving medicines in government clinics.

Civil society demands transparency and uninterrupted supply of TB medicines.

The high price of the GeneXpert platform and test is the main barrier to the sustainable scale-up of the technology.

Patients, TB organisations, treatment providers, medical practitioners, health NGOs, public interest groups, and treatment activists urge the Indian Prime Minister to take immediate steps to urgently address the issues of drug stockouts in India's TB programme.